SCHEMBL1713546

SCHEMBL1713546

CC1=NC(=Cc2c[nH]c3ncccc23)C(=O)N1CCN1CCOCC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 7/20 0.47
▸ PIM1 P11309 2/20 0.41
▸ PIM2 Q9P1W9 2/20 0.41
▸ CCNB2 O95067 1/20 0.41
▸ CDK1 P06493 1/20 0.41
▸ CCNB1 P14635 1/20 0.41
▸ CCNB3 Q8WWL7 1/20 0.41
▸ PIM3 Q86V86 1/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ HASPIN Q8TF76 4/20 0.40
▸ CCNT1 O60563 3/20 0.40
▸ CDK9 P50750 3/20 0.40
▸ DBF4 Q9UBU7 1/20 0.39
▸ CHEK1 O14757 1/20 0.39
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ AKR1B1 P15121 1/20 0.38
▸ APP P05067 1/20 0.38
▸ BCHE P06276 1/20 0.38
▸ ACHE P22303 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1713544 1.00 CDC7 (0.47) CDC7PIM1PIM2CCNB2CDK1
SCHEMBL1714107 0.86 KMT2A (0.47) CDC7PIM1PIM2PIM3KMT2A
SCHEMBL1714105 0.86 KMT2A (0.47) CDC7PIM1PIM2PIM3KMT2A
SCHEMBL1714401 0.85 CDC7 (0.42) CDC7PIM1PIM2CCNB2CDK1
SCHEMBL1714398 0.85 CDC7 (0.42) CDC7PIM1PIM2CCNB2CDK1
SCHEMBL1713471 0.79 KMT2A (0.51) CDC7PIM1PIM2CDK1PIM3
SCHEMBL1713472 0.79 KMT2A (0.51) CDC7PIM1PIM2CDK1PIM3
SCHEMBL1714402 0.79 AKR1B1 (0.45) CDC7PIM1PIM2PIM3KMT2A
SCHEMBL1714404 0.79 AKR1B1 (0.45) CDC7PIM1PIM2PIM3KMT2A
SCHEMBL5090060 0.78 CDC7 (0.42) CDC7PIM1PIM2PIM3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 CDC7 1/4885PIM1 431/4885PIM2 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback